BioCentury

7:00 AM GMT, Jul 3, 2006
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 6/30 cls
Anadys (ANDS) JMP Securities Adam Cutler Downgrade Market perform (from strong buy) -56% $2.92
Piper Jaffray Edward Tenthoff Downgrade Underperform (from market outperform)
ThinkEquity Andrew McDonald Price target Sell
Cutler downgraded the stock after ANDS suspended dosing in a Phase Ib trial of ANA975 to treat HCV because toxicology studies showed "intense" immune

Read the full 691 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.